Kodiak Sciences Inc. Stock Price, News & Analysis

Kodiak Sciences Inc. (Nasdaq: KOD) announced management presentations at two virtual investor conferences: the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 11:20 a.m. PT, and the Evercore ISI HealthCONx Conference on December 3, 2020, at 8:20 a.m. PT. A live webcast will be available on Kodiak's website, along with replays shortly after each event. Kodiak focuses on developing therapeutics for retinal diseases, highlighted by its lead candidate, KSI-301, targeting age-related macular degeneration and diabetic eye diseases.

Kodiak Sciences (Nasdaq: KOD) presented clinical data for KSI-301 at the AAO 2020 Virtual Annual Meeting, emphasizing its long-term efficacy and safety in treating diabetic macular edema (DME). The presentation, led by Dr. Arshad M Khanani, highlighted the promising durability and efficacy of KSI-301 compared to current anti-VEGF treatments. The ongoing Phase 3 GLEAM and GLIMMER studies aim to enroll approximately 450 patients each to assess KSI-301's impact on vision correction over two years. KSI-301 is positioned to address the significant treatment burden in diabetic eye diseases.

Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q3 2020 results, highlighting significant progress in clinical trials for KSI-301, a potential treatment for retinal diseases. The company completed U.S. enrollment for the DAZZLE study, with 545 out of 550 patients enrolled, expected to conclude by year-end 2020. Kodiak also initiated two Phase 3 studies in Diabetic Macular Edema and one in Retinal Vein Occlusion, aiming for a BLA submission in 2022. Despite a net loss of $36.1 million, Kodiak maintains a solid cash position of $380.5 million, projected to fund operations into 2022.

Kodiak Sciences Inc. (Nasdaq: KOD) announced on Oct. 5, 2020, that it has treated the first patients in pivotal Phase 3 studies for KSI-301, an anti-VEGF therapy targeting diabetic macular edema (DME) and retinal vein occlusion (RVO). The studies, GLEAM and GLIMMER, focus on treatment-naïve DME patients, while BEACON targets RVO patients. The ongoing DAZZLE study for wet AMD has completed U.S. recruitment. Initial Phase 1b results indicate that KSI-301 demonstrates significant durability with high treatment-free intervals. Kodiak aims to submit a BLA for KSI-301 by 2022.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical firm focused on retinal diseases, will present at two virtual investor conferences: the Citi 15th Annual BioPharma Conference on September 10 at 9:35 a.m. PT and the Morgan Stanley 18th Annual Global Healthcare Conference on September 17 at 10:15 a.m. PT. Webcasts of these presentations will be available on Kodiak's website, along with a limited-time replay option. Kodiak is advancing therapies aimed at preventing blindness caused by retinal conditions using its proprietary ABC Platform™.

Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q2 2020 results, highlighting significant advancements in their KSI-301 program targeting retinal diseases. CEO Victor Perlroth noted robust enrollment in the DAZZLE study for wet AMD, with 375 patients enrolled as of July 30, 2020. The company has a strong cash position of $417.1 million, but reported a net loss of $26 million. Increased R&D expenses of $20.6 million reflect ongoing clinical development. Kodiak remains on track for pivotal study initiations in 2020 and aims for a BLA submission in 2022.

Kodiak Sciences Inc. (Nasdaq: KOD) announced an R&D webcast on July 27, 2020, to discuss safety, efficacy, and durability data from its ongoing Phase 1b study of KSI-301 in treating retinal diseases like wet AMD, DME, and RVO. Management will review progress on the pivotal DAZZLE study in treatment-naïve wet AMD patients and planned pivotal studies for other conditions. KSI-301 aims to improve treatment outcomes and prevent vision loss in these diseases.

Kodiak Sciences (Nasdaq: KOD) announced positive data from its Phase 1b study of KSI-301, an anti-VEGF therapy for retinal diseases. Over 100 patient-years of data confirm KSI-301's safety and efficacy, with 82% of wet AMD and 76% of DME patients remaining treatment-free for four months post-initial doses. The therapy showed limited intraocular inflammation with significant vision improvements. Kodiak plans further pivotal studies in DME, RVO, and diabetic retinopathy, targeting a BLA submission by 2022, underpinned by strong clinical support and community engagement.

Kodiak Sciences Inc. (Nasdaq: KOD) announced that new data from the ongoing Phase 1b study of KSI-301, a novel anti-VEGF antibody biopolymer conjugate, will be presented at the ASRS 2020 Virtual Annual Meeting. The presentation will take place on July 10, 2020, showcasing results from 121 patients with wet AMD, diabetic macular edema, and retinal vein occlusion. CEO Victor Perlroth highlighted the promising safety and efficacy data accumulated across over 150 patient-years. A related R&D webinar is set for July 27, 2020, to discuss the implications of these findings.